Target intelligence / Profile preview

Sulfate anion transporter 1 (SLC26A1)

Target
SLC26A1
Molecular classification
Transporter, Anion exchanger, Solute carrier family protein
01

Overview

Sulfate anion transporter 1 (SLC26A1) is a member of the solute carrier (SLC26) protein family, functioning as a sodium-independent, electroneutral anion exchanger primarily expressed in the liver, kidney, brain, and intestine. SLC26A1 mediates bidirectional transport of sulfate, oxalate, chloride, bicarbonate, and thiosulfate ions across epithelial cell membranes to maintain systemic sulfate and oxalate balance. Loss-of-function mutations or deficiencies of SLC26A1 lead to impaired sulfate reabsorption, resulting in hyposulfatemia, increased urinary sulfate excretion, and predisposition to kidney stones, skeletal deficiencies, and other metabolic disorders. SLC26A1 is thus a recognized therapeutic target for potential intervention in conditions of sulfate dysregulation and nephrolithiasis.

Other names
SAT-1SAT1Sulfate/anion transporter SAT-1 proteinSolute carrier family 26 (anion exchanger) member 1Solute carrier family 26 (sulfate transporter) member 1EDM4CAONCAON1HYSULFSulfate anion transporter AT1
02

Mechanism of action

Inhibitors: Block anion exchange/transport function, e.g., DIDS competitively inhibits sulfate anion uptake. Potential modulation: Hypothetical future small molecules may restore function in loss-of-function mutants or regulate activity for therapeutic benefit.

03

Biological functions

Maintenance of sulfate homeostasisOxalate transport and regulationChloride, bicarbonate, and thiosulfate transportEpithelial ion balance
04

Disease associations

Nephrolithiasis (kidney stone disease)HepatotoxicityDistal renal tubular acidosisImpaired gastric secretionMusculoskeletal disease (including bone and cartilage disorders)Back pain and intervertebral disc disorderRenal calcinosis
05

Safety considerations

Disruption of anion homeostasis leading to metabolic acidosis, musculoskeletal disorders, or increased kidney stone risk with altered transporter functionPotential off-target effects on related anion homeostasis pathways if therapeutically targeted
06

Interacting drugs

4,4'-diisothiocyanato-2,2'-stilbenedisulfonic acid (DIDS; inhibitor)

1 more in the full profile.

07

Biomarkers

Genetic variants and mutations in SLC26A1 (e.g., Leu275Pro, Met132Thr, Leu348Pro) as biomarkers for sulfate handling disorders, nephrolithiasis riskPlasma and urine sulfate/oxalate levels for diagnosis and monitoring

Beyond the preview

Go deeper on Sulfate anion transporter 1 (SLC26A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sulfate anion transporter 1 (SLC26A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call